Almirall enters into Integrated Discovery Agreement with Proteros
Almirall, S.A. and Proteros biostructures GmbH announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases.
Under the agreement Proteros will apply its protein structure-based drug discovery platform. Proprietary site specific screening technologies, novel fragment libraries and structural biology will be deployed to support medicinal chemistry objectives of the program, to identify and optimize for selectivity and potency small molecule inhibitors of a specific enzyme.
Dr Jorge Beleta, Director Discovery Strategy and Alliances at Almirall remarked “we have worked with and been impressed by Proteros for many years on our structural biology and compound profiling projects and we see this broadening of our relationship to fully integrated projects as an exciting next step.”
Dr Torsten Neuefeind, Chief Executive Officer for Proteros commented ”we are delighted to be selected by Almirall as their partner for this programme. Proteros’s approach of knowledge driven fragment evolution has been validated within different protein classes and we look forward to demonstrating further success within this collaboration.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
